Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.
Hepatitis C virus (HCV) affects an estimated 3% of the population and is a leading cause of chronic liver disease worldwide. Since HCV therapeutic and preventative options are limited, the development of new HCV antivirals has become a global health care concern. This has spurred the development of cell-based infectious HCV high-throughput screening assays to test the ability of compounds to inhibit HCV infection. This unit describes methods that may be used to assess the in vitro efficacy of HCV antivirals using a cell-based high-throughput fluorescence resonance energy transfer (FRET) HCV infection screening assay, which allows for the identification of inhibitors that target HCV at any step in the viral life cycle. Basic protocols are provided for compound screening during HCV infection and analysis of compound efficacy using an HCV FRET assay. Support protocols are provided for propagation of infectious HCV and measurement of viral infectivity.
Yu
Xuemei
X
Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Uprichard
Susan L
SL
D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods*; D016174:Hepacivirus / Q000187:drug effects*; D006801:Humans
D000998:Antiviral Agents
J Biomol Screen. 1999;4(2):67-73
10838414
J Virol. 2001 Feb;75(3):1252-64
11152498
Anal Biochem. 1996 Jun 1;237(2):239-44
8660572
PLoS One. 2009 Aug 10;4(8):e6561
19668344
Hepatology. 2006 Sep;44(3):521-6
16941687
Science. 2005 Jul 22;309(5734):623-6
15947137
J Med Virol. 2001 Jul;64(3):334-9
11424123
Clin Pharmacol Ther. 2000 Nov;68(5):556-67
11103758
Nat Med. 2005 Jul;11(7):791-6
15951748
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9
15939869
Anal Biochem. 1996 Aug 15;240(1):60-7
8811880
Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53
15793110
Curr Protoc Mol Biol. 2001 May;Chapter 4:Unit4.2
18265236
Xenobiotica. 2009 Mar;39(3):205-17
19280519
J Virol. 2006 Feb;80(3):1181-90
16414995
J Virol. 2006 Nov;80(22):11082-93
16956932
Nat Med. 2008 Jan;14(1):25-7
18064037
Curr Protoc Mol Biol. 2004 Sep;Chapter 4:Unit 4.9
18265351
J Virol Methods. 1999 Jun;80(1):77-84
10403679
Gastroenterology. 2003 Dec;125(6):1808-17
14724833
J Virol. 2006 Oct;80(20):10253-7
17005703
Curr Protoc Cell Biol. 2007 Sep;Chapter 1:Unit 1.1
18228494
Cancer Res. 1982 Sep;42(9):3858-63
6286115
J Virol. 2005 Nov;79(21):13778-93
16227297
Semin Liver Dis. 2000;20(1):17-35
10895429
Antimicrob Agents Chemother. 2009 Oct;53(10):4311-9
19620334
Curr Protoc Mol Biol. 2006 Nov;Appendix 3:Appendix 3D
18265369
Prep Biochem. 1978;8(1):1-17
643823
J Virol. 2003 May;77(9):5487-92
12692249
Nature. 2005 Aug 18;436(7053):933-8
16107832
Anal Biochem. 1987 Apr;162(1):156-9
2440339